

**Pegasparginase, Gemcitabine, Oxaliplatin (P-GemOx). Natural Killer Cell Lymphoma.**

MRN:   
Ward/Unit:   
Name:   
DOB:   
Address:   
NHS No:   
Consultant:   
NHS No:

Hb   
WBC   
Plt   
Neuts   
PT   
APTT   
Fibrinogen

Na+   
K+   
Urea   
Cr   
GFR   
Ca   
Mg

Alb   
ALP   
ALT   
Bili   
Amylase   
Glucose

Height   
Weight   
BSA   
Date   
Allergies:   
Nature of allergy:

Recorded by:   
Date:   
Date:   
Date:

Emetogenic potential: Moderately emetogenic   
Extravasation classification: Oxaliplatin—irritant.   
Gemcitabine and Peg-asparaginase—non-vesicant.   
Hepatitis B serology:   
Treatment intent: Palliative   
Cycle number:

To be given every 21 days. First 2 courses prior to radiotherapy then 2-4 courses after radiotherapy.

Tick if EBV PCR has been checked ☐

Day No. Date	DRUG or ELECTROLYTE	CALCULATION	DOSE	IV FLUIDS	VOL. MLS.	ROUTE/FLOW RATE	SPECIAL DIRECTIONS/ ADMINISTRATION DETAILS	DRUG ADMINISTRATION	TIME	Pharmacy
1	Akynzeo		One capsule	Oral			1 hour prior to chemotherapy	Sig.	Sig.	
	Famotidine		20mg	Oral			30min - 1h pre Pegasparginase			
	Paracetamol		1000mg	Oral			30min - 1h pre Pegasparginase			
	Chlorphenamine		10mg				IV bolus 30min pre- pegasparginase			
	Dexamethasone		8mg				IV bolus 30min pre- pegasparginase			
	PEGASPARAGINASE	2000 units/m <sup>2</sup>		Intramuscular						
	GEMCITABINE	1000mg/m <sup>2</sup>		Sodium Chloride 0.9%	50ml	IV over 5 mins	IV infusion to flush line			
				Sodium Chloride 0.9%	250ml	IV infusion over 30 mins				
				Glucose 5%	50ml	IV over 5 mins	IV infusion to flush line			
	OXALIPLATIN	130mg/m <sup>2</sup>		Glucose 5%	250ml	IV infusion over 2 hours				
				Glucose 5%	50ml	IV over 5 mins	IV infusion to flush line			

Prescriber sig: ..... Name: ..... Date: ..... Pharmacist initial sig: ..... Name: ..... Date: .....



Pegasparginase, Gemcitabine, Oxaliplatin (P-GemOx). Natural Killer Cell Lymphoma.

MRN: Ward/Unit:

Name: Consultant:

DOB:

Address:

NHS No:

Hb

WBC

Plt

Neuts

PT

APTT

Fibrinogen

Na+

K+

Urea

Cr

GFR

Ca

Mg

Alb

ALP

ALT

Bili

Amylase

Glucose

Height

Weight

BSA

Date

Allergies:

Nature of allergy:

Recorded by

Date

Funding status: N/A

Emetogenic potential: Moderately emetogenic

Extravasation classification: Oxaliplatin—irritant.

Gemcitabine and Peg-asparaginase—non-vesicant.

Hepatitis B serology:

Treatment intent: Palliative

Cycle number:

To be given every 21 days. First 2 courses prior to radiotherapy then 2-4 courses after radiotherapy.

Tick if EBV PCR has been checked ☐

Day No. Date	DRUG or ELECTROLYTE	CALCULATION	DOSE	IV FLUIDS	VOL. MLS.	ROUTE/ RATE	SPECIAL DIRECTIONS/ ADMINISTRATION DE- TAILS	DRUG ADMINISTRATION Sig.	Sig.	TIME	Pharmacy
	Metoclopramide		10mg	Sodium Chloride 0.9%	50ml	IV over 5 mins	IV infusion to flush line				
				Sodium Chloride 0.9%	50ml	IV over 5 mins	IV infusion to flush line				
8	GEMCITABINE	1000mg/m <sup>2</sup>		Sodium Chloride 0.9%	250ml	IV infusion over 30 mins	IV infusion to flush line				

Medications to be prescribed on PICs		Supportive medication	
Anti-emetics			
Metoclopramide 10mg TDS PO PRN		Allopurinol 300mg OD for cycle 1 only	
Dexamethasone 4mg BD PO for 3 days starting on day 1		Aciclovir 400mg BD	
		Co-trimoxazole 480mg BD M/W/F	
		Filgrastim as required	

Prescriber sig: Name Date

Pharmacist initial sig: Name Date



Pegasparginase, Gemcitabine, Oxaliplatin (P-GemOx). Natural Killer Cell Lymphoma.

Proceed rules

FBC valid within 96 hours of day 1, with 48 hours of day 8. (U+E's/LFTs within 7 days of day 1):

Drug	Neuts ( x 10 <sup>9</sup> /L)	Platelets ( x 10 <sup>9</sup> /L)	Dose Modification	Renal	Hepatic
Gemcitabine and Oxaliplatin Day 1	≥1.0	≥75	100% dose	<b>Oxaliplatin:</b> CrCl ≥ 30 ml/min— No dose adjustment needed  CrCl < 30 ml/min— discuss with con- sultant, consider 50% dose  <b>Gemcitabine:</b> Bilirubin ≥27µmol/L— Consider starting at 80% dose	<b>Oxaliplatin :</b> N/A
	<1.0	≥75	Delay 1 week If platelets >75 resume at 100% If platelets 50-75 resume at 100% dose with platelet support If platelets < 50 resume at 75%		
	<1.0	<75	Delay 1 week If neuts > 1.0 resume at 100% with GCSF support		
	<1.0	<75	Delay 1 week If neuts > 1.0 platelets >75 resume at 100% with GCSF support If platelets 50-75 resume at 100% dose with platelet support If platelets < 50 resume at 75%		
Gemcitabine Day 8	≥1.0	≥75	100% dose	<b>Gemcitabine:</b> N/A	
	<1.0	<75	Contact prescriber		
Pegasparginase	≥1.0	≥75	100% dose		
	<1.0	<75	Contact prescriber		

If amylase > 3 x ULN, fibrinogen < 0.5 g/L, or new onset significant LFT derangement contact prescriber

Prescriber sig: .....Name:.....Date:.....

Pharmacist initial sig: .....Name:.....Date:.....



Rota code: HROTA423	Issue date: June 2024	Written by: Steve Hill	Authorised by: Prem Mahendra	Page: 4 of 4
Version no. 1.0	Valid until: Next review	Checked by (Pharmacist)	Clinical Nurse Specialist:	Reference: Zhang et al. Am J Hematol. 2021;96:1481-1490.
		<i>28/06/2024</i>	<i>K Stockton</i>	

**Pegasparginase, Gemcitabine, Oxaliplatin (P-GemOx). Natural Killer Cell Lymphoma.**

**Other Information**

**Pegasparginase:**

For Pegasparginase, monitor BP and vitals and visual inspection of injection site before and after injection, observe for 1 hour after injection

Fresh frozen plasma not recommended

**Oxaliplatin:**

If the neurosensory toxicity is NCI-CTC grade 1–2 and lasts less than 7 days administer full dose oxaliplatin. If the toxicity is NCI-CTC grade 2 and persists for more than 7 days reduce the oxaliplatin dose to 97.5mg/m2. Oxaliplatin should be discontinued for neurosensory toxicities NCI-CTC grade 3 or above.

If NCI-CTC grade 3-4 diarrhoea or stomatitis recurs despite appropriate reduction in the dose the oxaliplatin dose should be reduced to 97.5mg/m2.